Mortality within Ninety Days of Hemoglobin Correction Among Newly Diagnosed Solid Cancer Patients with Anaemia at Bugando Medical Centre Mwanza. (Record no. 18786)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05798nam a22003137a 4500 |
| 001 - CONTROL NUMBER | |
| control field | CUHAS/MMED/6000247/T/18 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | CUHAS/MMED/6000247/T/18 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240423163754.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 231123b |||||||| |||| 00| 0 eng d |
| 028 ## - PUBLISHER OR DISTRIBUTOR NUMBER | |
| Source | Wurzburg Road 35, BMC Premises, Post Code: 33102: |
| Source | P. O. Box 1464, Mwanza – Tanzania: |
| Source | Phone: +255 28 298 3384: |
| Source | Fax: +255 28 298 3386: |
| Source | Email: vc@bugando.ac.tz: |
| Source | www.bugando.ac.tz |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | CUHAS/MMED/6000247/T/18 |
| 040 ## - CATALOGING SOURCE | |
| Language of cataloging | English |
| Transcribing agency | DDC |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Salustia Aloyce Bugingo |
| Dates associated with a name | [Female] |
| Relator term | CUHAS/MMED/6000247/T/18 |
| 245 ## - TITLE STATEMENT | |
| Title | Mortality within Ninety Days of Hemoglobin Correction Among Newly Diagnosed Solid Cancer Patients with Anaemia at Bugando Medical Centre Mwanza. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mwanza, Tanzania: |
| Name of publisher, distributor, etc. | Catholic University of Health and Allied Sciences [CUHAS – Bugando] : |
| Date of publication, distribution, etc. | 2023 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 86 Pages |
| Extent | Includes References and Appendices |
| 520 ## - SUMMARY, ETC. | |
| Source | <br/>Abstract:<br/><br/>Background: Anaemia is a common finding in cancer that is caused by several factors. Cancer-related low hemoglobin adversely affects the quality of life, worsens disease status, impairs treatment outcomes, and is associated with reduced overall survival. Anemia is a clinical status distinguished by a decreased erythrocyte mass with subsequent low hemoglobin and hematocrit counts. Mortality due to low hemoglobin levels among cancer patients is reported to be significantly high within the first 90 days of therapy. This could be due to tissue hypoxia which reduces the drugs delivered to the cells and hence interferes with the disease's response to therapy. A study conducted on 90 days' survival in solid cancer patients at Bugando medical center, reported a mortality rate of 11.8 % with a majority of deaths occurring among patients with low hemoglobin at baseline. This suggests a clinically significant association between survival and low hemoglobin level. Early hemoglobin correction was potential for treatment efficiency and increases survival rate. Currently, low hemoglobin correction in solid cancer patients at Bugando medical center depends on the attending physician's decision. This practice may contribute to disease progression and poor survival. Anemia-related mortality was found to be common in this population. Urgent restoration is important for potential local tumor control and survival at Bugando medical center.<br/><br/>Objective: To determine ninety days’ mortality following Hb correction among newly diagnosed solid cancer patients with anaemia receiving oral iron supplement plus or minus red blood cells at Bugando medical center.<br/><br/>Methodology: It was a hospital-based interventional longitudinal study in newly diagnosed solid cancer patients with hemoglobin levels ≤11.9 g/dl who planned to receive cancer treatment for curative intent. Both inpatient and outpatient attending at oncology department Bugando medical center between December 2022 and June 2023 were involved. A total of 236 patients were enrolled in the study aged 18 years and above. Face-to-face interviews were conducted using structured questionnaires, history taking and physical examination and a review of medical records for cancer type and cancer stage were done by the principal investigator. Venous blood was collected at baseline for a complete blood picture. Hemoglobin correction was done to all patients with hemoglobin ≤ 11.9 g/dl. For patients with hemoglobin level < 8g/dl were given using oral iron supplement plus red blood cells transfusion for Hb correction. Cancer therapy was given to all patients who maintained hemoglobin ≥ 8g/dl. Furthermore, all patients were followed for 90 days for mortality assessment starting from the day of hemoglobin correction. STATA version 15.0 software was used for data analysis.<br/><br/>Results: Of 236 patients who participated in this study; 144 (61.02%) were female, and 140 (59.32%) were aged ≤ 60 years and majority were from the lake zone 94.92%. The prevalence of anaemia was 88.7%, with a median hemoglobin 10 [9-11], and about 71.61% of patients had mild anaemia. The commonest cancer types anatomically were gynecological 54 (22.88%) and gastrointestinal cancers 51(21.61%). Breast, genital and reproductive cancers were the second most 31(13.14%) and 30(12.51%), respectively. Among specific cancer subtypes, cancer of the cervix was 53 (22.45%) has high prevalent in all cancer followed by breast cancer 31(13.14%), prostate cancer 26 (11.2%), hepatocellular carcinoma 16 (6.78%) and esophageal cancer16 (6.78%). Majority of anaemic patients (92.80%) received oral iron supplement for hemoglobin correction and a total of 25 (10.7%) patients died within 90 days of following hemoglobin correction. Cancer stage (OR; 1.97; 95% CI 1.04-3.74; p-value =0.037), poor performance status (OR; 2.54; 95% CI 1.11-5.74; p value=0.026), multiple comorbidities (OR;6.01; 95% CI 2.10- 17.18; p-value = 0.001) were factors associated with mortality. <br/><br/>Conclusion. We have observed a high prevalence of anaemia in solid cancer patients, cervical, breast cancer, prostate cancer and gastrointestinal cancer remained the dominant among all solid cancer types. Mortality within 90 days of therapy was slightly lower than that reported by the previous study, blood transfusion, and an oral iron supplement might have a positive effect on Hb dynamics and maintained Hb level ≥ 8/g/dl pretherapy. Poor performance status, cancer stage, and comorbid conditions showed a statistically significant association with 90 days' mortality.<br/> |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Internal Medicine |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 292007 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | POSTGRADUATE DISSERTATIONS |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 11/23/2023 | CUHAS/MMED/6000247/T | 11/23/2023 | 11/23/2023 | POSTGRADUATE DISSERTATIONS |